Dariusz Kowalski

Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as Eerstelijns Behandeling for Unresec...

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 maart 2026

T-DXd bij HER2-overexpresserend NSCLC: DESTINY-Lung01 deel 1 resultaten

Journal of Thoracic Oncology · 23 december 2025

Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Fase III IPSOS Study.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025-12

A Pooled Analysis of Datopotamab Deruxtecan in Patiënten met EGFR-Mutated NSCLC.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025-11

The Phase 3 KEYLYNK-006 Study of Pembrolizumab Plus Olaparib Versus Pembrolizumab Plus Pemetrexed as Maintenance Ther...

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025-02

Subcutaan versus IV amivantamab plus lazertinib bij EGFR-gemuteerd NSCLC: PALOMA-3

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 oktober 2024

Eerstelijns atezolizumab mono versus chemotherapie bij NSCLC: IMpower110 langetermijn

Lancet (London, England) · 5 augustus 2023

Totale overleving met adjuvant osimertinib bij gereseceerd EGFR-gemuteerd NSCLC: ADAURA definitieve OS

The New England journal of medicine · 13 juli 2023

Nivolumab plus ipilimumab bij irresectabel mesothelioom: CheckMate 743 fase III

Lancet (London, England) · 30 januari 2021

Ganetespib plus docetaxel versus docetaxel bij gevorderd NSCLC: GALAXY-2 fase III

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 februari 2020

QoL met carboplatine-paclitaxel/nab-pac met of zonder pembrolizumab bij NSCLC: KEYNOTE-407 analyse

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 januari 2020

Roniciclib plus etoposide-platina bij eerstelijns SCLC: fase II

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2019-04

Tremelimumab bij recidief mesothelioom: DETERMINE multicentrische fase IIb-studie

The Lancet. Oncology · 2017-09